AM-710 is an ultra-long-acting injectable GLP-1 receptor agonist with a potential best-in-class profile, and is in development for once-every-three-month, once-every-six-month, or longer dosing intervals.
Publications
Preclinical characterization of AM-710, a novel ultra-long-acting small-molecule GLP1R agonist
Aion team has developed drugs which have generated over $100 billion in revenue.
OUR TEAM
Alborz Yazdi
Co-Founder and CEO
Brian Kearney, PharmD
Chief Scientific and Development Officer
Benson Edagwa
SVP, Head of Discovery
Gary Elliott
CMC
Nick Morra
CMC
Michael Crowley
CMC
ADVISORS
Tim Garnett
Former Chief Medical Officer, Lilly
Steven Grinspoon
Head of Metabolism at Harvard MGH
Edward V. Nunes, MD
Head of Addiction Psychiatry at Columbia
Frank Vocci
Former Head of Drug Abuse at FDA, Opioid Abuse NIDA
Paul J Kenny, PhD
Chair of Neuroscience & Director of Drug Discovery at Mount Sinai
John Pottage
Former CSO & CMO, ViiV / GSK
News
Aion Medicines presents data at ObesityWeek demonstrating ultra-long-acting PK and PD of AM-710, a potential best-in-class GLP-1 receptor agonist and the longest acting incretin identified to date
.webp)
.webp)
.webp)
%402x.svg){kind=icon}